Concord Biotech Ltd. · NSE:CONCORDBIO
Concord Biotech — Q1 FY2027 Earnings Presentation
26 slides from Concord Biotech's earnings presentation, Aug 1, 2026
Slide 1: Concord Biotech Limited exchange filing cover letter
CONCORD BIOTECH LIMITED B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat. Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440 Email ID: complianceofficer@concordbiotech.com ------------------------------------------------------
Slide 2: Investor Presentation – August 2026
Investor Presentation – August 2026
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Concord Biotech Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any secur
Slide 4: Q1FY27 Key Financial Highlights
Q1FY27 Key Financial Highlights
Slide 5: Q1FY27 Key Highlights
Q1FY27 Key Highlights Broad based Growth • Witnessed broad based growth across All Product Categories • Growth across geographies with Exports growing by ~46% for Q1FY27 (Y-o-Y) Wallet Share Growth & Customer Acquisition • Increase in wallet share among existing customer along with Addition of New P
Slide 6: Q1FY27 Consolidated Financial Highlights
Q1FY27 Consolidated Financial Highlights Revenue (Rs. in Crs) EBITDA (Rs. in Crs) PAT (Rs. in Crs) +26% +34% +31% 257.5 82.4 57.7 204.0 61.4 44.1 Q1FY26 Q1FY27 Q1FY26 Q1FY27 Q1FY26 Q1FY27 Gross Profit Margin (%) EBIDTA Margin (%) PAT Margin (%) 100 bps 190 bps 80 bps 77.9% 78.9% 30.1% 32.0% 21.6% 22
Slide 7: Q1FY27 Segment wise Revenue Split
Q1FY27 Segment wise Revenue Split API Revenue (Rs. in Crs) Formulation Revenue (Rs. in Crs) Total Revenue (Rs. in Crs) +42% +26% -23% 218.9 50.2 257.5 38.6 204.0 153.8 Q1FY26 Q1FY27 Q1FY26 Q1FY27 Q1FY26 Q1FY27 Domestic Revenue (Rs. in Crs) Exports Revenue (Rs. in Crs) Total Revenue (Rs. in Crs) +12%
Slide 8: Management Commentary
Management Commentary Commenting on the Q1 FY27 performance of the company Mr. Ankur Vaid, Joint Managing Director & Chief Executive Officer for Concord Biotech Limited said, “We are pleased to report a strong revenue growth of 26% year-on-year in Q1FY27, driven by broad-based performance across pro
Slide 9: Q1FY27 Consolidated Profit & Loss Account
Q1FY27 Consolidated Profit & Loss Account Profit and Loss (Rs. in Crs) Q1FY27 Q1FY26 YoY Revenue from Operations 257 204 26.2% Cost of Goods Sold 54 45 Gross Profit 203 159 27.9% Gross Profit Margin 78.9% 77.9% 100 bps Employee Cost 44 38 Other Expenses 77 60 EBITDA 82 61 34.2% EBITDA Margin 32.0% 3
Slide 10: Company Overview
Company Overview
Slide 11: Concord Biotech at a Glance
Concord Biotech at a Glance Concord Biotech Limited is a R&D driven biopharma Company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. Key Highlights Leading & Prominent Player in World Leadership Position in Portfolio
Slide 12: Driving Innovation Through Our Expertise
Driving Innovation Through Our Expertise Fermentation Expertise Through our strong fermentation capabilities, we produce high-quality APIs, setting us apart in biotechnology and ensuring superior efficacy in medicines Mission Focus Dedicated to deliver high-quality product that enhance human health,
Slide 13: API Business Overview
API Business Overview API Overview One of the leading global developers and Focus on Niche Fermentation API’s with Diversified Product Portfolio of API’s including manufacturers of Fermentation-based APIs backward integration to Key Starting Material Immuno-suppressant, Oncology, Anti- Infectives &
Slide 14: Formulation Business Overview
Formulation Business Overview Formulation Overview Operate through B2B model across regulated Oral Solid Dosages (tablets, capsules, softgel and oral Commercialization of Formulations business in suspension) 2016 to capitalize on the benefits of backward and emerging markets Injectables (Liquid Vial
Slide 15: Trusted CDMO partner for Fermentation & Semi-Synthetic API's
Trusted CDMO partner for Fermentation & Semi-Synthetic API’s CDMO Overview Prioritizes innovation, backed by a DSIR- Expertise in fermentation technology and strong Provide contract research and manufacturing R&D infrastructure enable us to undertake complex certified R&D facility with a team of 180
Slide 16: Pushing Boundaries through Manufacturing Capabilities
Pushing Boundaries through Manufacturing Capabilities Unit I (API) – Dholka, Gujarat Unit II (Formulations) – Valthera, Gujarat FY2000 Operations commenced FY2016 Operations commenced 1,12,302 sq.m. Spread across 94,826 sq.m. Spread across 450 m3 Installed capacity 869Mn Units Installed capacity Uni
Slide 17: Pioneering R&D Capabilities
Pioneering R&D Capabilities R&D Initiatives: State-of-the-Art Facilities: Where Ideas Materialise 187 12/7 R&D Employee Approved ANDA/ API R&DLab Strength Finished Products Cost Improvement • Specialized capabilities for isolation of strains, mutation, and passive selection of microbial strains, as
Slide 18: DMF Filings Across Geographies
DMF Fillings Across Geographies Molecules US EU Canada Japan China Tacrolimus ✓ ✓ ✓ ✓ ✓ Mycophenolate Mofetil ✓ ✓ ✓ ✓ ✓ Suppressants Mycophenolate Sodium ✓ ✓ ✓ ✓ Immuno- Cyclosporine ✓ ✓ ✓ ✓ ✓ Sirolimus ✓ ✓ ✓ ✓ Pimecrolimus ✓ Voclosporin ✓ Temsirolimus ✓ ✓ Everolimus ✓ ✓ ✓ ✓ Oncology Romidepsin ✓ ✓
Slide 19: Wide Range of Formulation Product Portfolio for Overseas Markets
Wide Range of Formulation Product Portfolio for Overseas Markets Regulated Markets Emerging Markets Product Name ANDA Approval Product Name Mycophenolate Mofetil Capsules Mycophenolate Mofetil Capsules Mycophenolate Mofetil Tablets Mycophenolic Acid DR Tablets USP Mycophenolate Mofetil Suspension My
Slide 20: Diversified Customer Base
Diversified Customer Base 70+ 300+ Countries Customers Reducing Customer Concentration % Contribution from Top 10 Customers 37.6% FY26 37.8% FY25 42.0% FY24 FY23 44.3% Worldwide Presence Tailored Distribution Models FY22 47.7% Collaborative Partnerships 19
Slide 21: Paving the Way for Sustainability
Paving the Way for Sustainability Our Vision for Sustainability The Path of Sustainability Sustainable Manufacturing Research & Development Efficient Resource Management Global Green Leadership Constant Improvement & Adaptation Environmental Conservation Awarded Silver Medal by EcoVadis Our Initiati
Slide 22: Key Business Differentiators
Key Business Differentiators
Slide 23: End-to-End Expertise in Complex Fermentation Value Chain
End-to-End Expertise in Complex Fermentation Value Chain Overview of Integrated Platform Leadership Position 1,250 M3 Leadership position for select molecules Fermentation Capacity across two in global markets API facilities R&D Patents 01 02 03 04 Key Starting Material API Manufacturing Over 2 Deca
Slide 24: Constructing Formidable Barriers to Entry
Constructing Formidable Barriers to Entry Significant Capital Intensive Operational Complex Process & Infrastructural Requirements Long gestation Period Entry Barriers Technical Expertise Requirements (large scale fermenters) Complex technical capabilities, difficulties in scaling up operations and
Slide 25: Key Growth Drivers
Key Growth Drivers API Business Expanding API Marketing existing APIs Increasing wallet share Portfolio to new customers with existing customers 01 Formulations Business CONCORD BIOTECH Expanding portfolio through own development & in- Launching new dosage forms including Expanding geographic reach
Slide 26: For further Information, please contact
For further Information, please contact Company: Investor Relations Advisor: Concord Biotech Limited Strategic Growth Advisors Pvt. Ltd. CIN: L24230GJ1984PLC007440 CIN - U74140MH2010PTC204285 Mr. Raviraj Karia – Chief Financial Officer ravirajkaria@concordbiotech.com Mr. Sagar Shroff / Mr. Vatsal Sh